Quality of life of patients with chronic obstructive pulmonary disease treated with indacaterol 
and/or glycopyrronium: a real-world Polish observational study

Płusa, Tadeusz

doi:10.5114/amscd.2018.81306

Cited by 3 publications

(1 citation statement)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a recent multicenter study from Poland, smoking history was reported in 92.6% of patients with stable chronic obstructive pulmonary disease [25].…”

Section: Gangrene and Necrosis Of Lungmentioning

confidence: 98%

Lung and mediastinum abscesses in Poland: a national hospital register-based study

et al. 2020

View full text Add to dashboard Cite

IntroductionAirway infections represent one of the most common causes of mortality worldwide. The authors sought to describe patients hospitalized for lung and mediastinum abscesses in Poland from 2009 to 2016. To the authors’ knowledge, this is the first evaluation of the disease in Poland.Material and methodsThe authors conducted a retrospective, population- based study, using data from 14,932 hospital discharge records. Lung and mediastinum abscesses incidence rates were estimated on the basis of data from a Polish hospital morbidity study, carried out by the National Institute of Public Health.ResultsThe study group consisted of 12,049 patients (74.3% male and 25.7% female patients) hospitalized for the first time with the diagnosis of lung or mediastinum abscesses. The mean and median age was 57.2 and 59 years, respectively. The mean age was significantly higher in females than males (57.9 years vs. 57 years, p < 0.05). Patients were hospitalized with the following diagnosis: abscess of lung with pneumonia (60.9%), abscess of lung without pneumonia (24.9%), abscess of lung and mediastinum (2.6%), gangrene and necrosis of lung (2.8%), abscess of mediastinum (9.7%). The average annual incidence of lung abscesses, including gangrene or necrosis of lung, was 35.7 per million (95% CI: 34.1–37.4) and the average annual incidence of mediastinum abscess was 4.8 per million (95% CI: 4.3–5.3). The incidence rates for all cases of lung or mediastinum abscesses did not vary significantly between urban and rural regions.ConclusionsPresented recent data on lung and mediastinum abscesses in Poland may be helpful in comparative analyses among European countries.

show abstract

“…In a recent multicenter study from Poland, smoking history was reported in 92.6% of patients with stable chronic obstructive pulmonary disease [25].…”

Section: Gangrene and Necrosis Of Lungmentioning

confidence: 98%

Lung and mediastinum abscesses in Poland: a national hospital register-based study

et al. 2020

View full text Add to dashboard Cite

show abstract

Elderly age group patients with COPD continuing to smoke -a problem that cannot be ignored

Купаев¹,

Osipov²

2020

Medicine in Drug Discovery

View full text Add to dashboard Cite

Which bronchodilator to choose if a patient with chronic obstructive pulmonary disease continues to smoke?

Купаев

Osipov

2021

Pulʹmonologiâ (Mosk.)

View full text Add to dashboard Cite

From 30 to 43% of smoking patients with chronic obstructive pulmonary disease (COPD) cannot give up nicotine despite the diagnosis and deterioration of health. Most of the publications related to the treatment of COPD do not distinguish smoking patients into a separate group. The aim of this study is a comparative analysis of the effectiveness of long-acting muscarinic antagonists (LAMA), LAMA/long-acting β2 -agonists (LABA) in smoking patients.Methods. The study involved 121 patients with a high degree of nicotine addiction and irreversible bronchial obstruction. All the patients continued to receive bronchodilator therapy. The respondents were divided into two groups: patients who quit smoking and patients who continued to smoke. In turn, each group was divided into two subgroups depending on the treatment – LAMA (Tiotropium 5 μg and Glycopyrronium 50 μg) and LAMA/LABA (tiotropium/olodaterol 5/5 μg and glycopyrronium/idacaterol 50/110 μg). We used the changes of FEV1 and the dynamics of CAT (COPD Assessment Test) as the comparison criteria.Results. The results of the CAT and spirometry showed a tendency to improve in both groups, regardless of the treatment regimen. However, the improvement in symptoms and spirometry parameters were more pronounced in the group of patients who quit smoking: –1 and –11 points, respectively (p < 0.05) and 12 and 23%, respectively (p < 0.05). Comparison of the efficacy of various treatment regimens in the group of smoking patients showed there was no statistically significant difference between LAMA and LAMA/LABA neither in spirometry parameters (11.45 and 13.1%; p < 0.05), nor in the CAT scores (–1.5 and –1.67; p < 0.05). However, combination therapy (LAMA/LABA) was more effective than monotherapy (LAMA) in the group of patients who quit smoking both according to spirometry (25.5 and 13%, respectively; p < 0.05) and CAT (–12.3 and –5.9, respectively; p < 0.05). There was no statistically significant difference between the active substances both in the monotherapy group (tiotropium/glycopyrronium) and in the combination group (tiotropium/olodaterol and glycopyrronium/indacaterol).Conclusion. According to CAT and spirometry, there was no difference between tiotropium and glycopyrronium, nor was there a difference between fixed-dose combinations of tiotropium/olodaterol and glycopyrronium/ indacaterol (both in the group of smokers and in the group of non-smokers). Smoking cessation is key to improving both spirometry and CAT results.

show abstract

Quality of life of patients with chronic obstructive pulmonary disease treated with indacaterol and/or glycopyrronium: a real-world Polish observational study

Cited by 3 publications

References 17 publications

Lung and mediastinum abscesses in Poland: a national hospital register-based study

Lung and mediastinum abscesses in Poland: a national hospital register-based study

Elderly age group patients with COPD continuing to smoke -a problem that cannot be ignored

Which bronchodilator to choose if a patient with chronic obstructive pulmonary disease continues to smoke?

Contact Info

Product

Resources

About